Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and / Najlacnejšie knihy
Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Kód: 05284264

Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Autor Malik Osmane

Master's Thesis from the year 2013 in the subject Medicine - Pharmacology, grade: 1 st CLASS HONS, Dublin Institute of Technology (Chemistry), course: Pharmaceutical Quality Assurance / Regulatory Affairs, language: English, abstr ... celý popis

145.98


Skladom u dodávateľa
Odosielame za 14 - 18 dní
Pridať medzi želanie

Mohlo by sa vám tiež páčiť

Darujte túto knihu ešte dnes
  1. Objednajte knihu a vyberte Zaslať ako darček.
  2. Obratom obdržíte darovací poukaz na knihu, ktorý môžete ihneď odovzdať obdarovanému.
  3. Knihu zašleme na adresu obdarovaného, o nič sa nestaráte.

Viac informácií

Viac informácií o knihe Rift-lines within European regulatory framework for Biosimilars when taking heterogeneity and variation during lifecycle of the reference biologic and

Nákupom získate 360 bodov

Anotácia knihy

Master's Thesis from the year 2013 in the subject Medicine - Pharmacology, grade: 1 st CLASS HONS, Dublin Institute of Technology (Chemistry), course: Pharmaceutical Quality Assurance / Regulatory Affairs, language: English, abstract: During the course of this thesis evidence was presented and discussed related to the research questions. The fundamental question related to the heterogeneity and variation through the life cycle of the biosimilar and the reference biologic remains neglected, based on the results collected during this thesis, by the stakeholders, mainly because those issues where not addressed in any official regulatory guidance document. §As clear guidance from the EMA is lacking, with the only available guidance being that once a marketing authorization is issued it is accepted that the quality profiles of the reference biologic and the biosimilar will have different quality profiles. §Abstract:§Within the biosimilar development context, there are unaddressed questions by the European Medicines Agency (EMA) with regard to the impacts of shifts of the quality profile (purity- and impurity levels) of the reference biologic for the biosimilar development program. This dynamic is an open issues has potentially implications on the comparability exercise of the before mentioned.§Opinions from experts involved in the guidance drafting process of EMA and other were evaluated with regard to the issue.[...]

Parametre knihy

Zaradenie knihy Knihy po anglicky Medicine Nursing & ancillary services Pharmacy / dispensing

145.98

Obľúbené z iného súdka



Osobný odber Bratislava a 2642 dalších

Copyright ©2008-24 najlacnejsie-knihy.sk Všetky práva vyhradenéSúkromieCookies


Môj účet: Prihlásiť sa
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Nákupný košík ( prázdny )

Vyzdvihnutie v Zásielkovni
zadarmo nad 59,99 €.

Nachádzate sa: